MorphoSys AG

Type: Company
Name: MorphoSys AG
Nationality: Germany
Web Address: http://www.morphosys.com/
First reported 12 hours ago - Updated 12 hours ago - 1 reports

MorphoSys Provides Update on the Company's Proprietary Drug Portfolio

Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs. ... [Published Technology Networks - 12 hours ago]
First reported Jul 28 2014 - Updated 15 hours ago - 3 reports

BRIEF-Morphosys shares rise after Q2 results

8:10am BSTJuly 28 (Reuters) - Shares in Morphosys AG rise 2.6 percent at open after Q2 results ... [Published Reuters UK - Jul 28 2014]
Entities: MorphoSys AG
First reported Jul 28 2014 - Updated Jul 28 2014 - 5 reports

MorphoSys highlights pipeline as Q2 shows loss

MorphoSys AG reported a loss for the second quarter due largely to an unfavourable comparison with the previous period when earnings were inflated by a licensing deal with GlaxoSmithKline Plc. However, the company expects its loss for the year as a whole ... [Published MedNous - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Alzheimer’s therapies could result in $12B market by 2023

The industry for Alzheimer’s drug treatments is expected to grow from modest beginnings to big business in the next decade, according to a June report by Decision Resources Group.The analysis estimates that the market for Alzheimer’s therapies will more ... [Published MolecularImaging.net - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Share buy-back week 30/2014

1Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines2Alcon's Simbrinza® approved in the EU to treat patients living with glaucoma, a chronic sight-threatening eye disease3MorphoSys Provides Update on ... [Published EuroInvestor - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Morphosys AG gives FY 2014 guidance in line with analysts' estimates

6:30am BSTMorphosys AG:Sees FY 2014 total revenues of 58 million euros to 63 million euros.Sees FY 2014 EBIT in the range of -(11) million euros to - (16) million euros.FY 2014 revenues estimates of 61 million euros - Thomson Reuters I/B/E/S.FY 2014 EBIT ... [Published Reuters UK - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 2 reports

MorphoSys AG Reports Results for the First Six Months of 2014

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced its financial results for the six months ending 30 June 2014. Group revenues from continuing operations were EUR 30.5 million (H1 2013: EUR 48.2 million). ... [Published Virtual Strategy Magazine - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys H1 Profit Decreases; Re-confirms Guidance For 2014

MorphoSys AG (MPSYY.PK) reported earnings before interest and taxes (EBIT) from continued operations of 0.4 million euros for the six months ending 30 June 2014, compared to 17.3 million euros, a year ago. Profit from continuing operations decreased to ... [Published RTTNews.com - Jul 28 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

MorphoSys AG Reports Results for the First Six -2-

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. ... [Published Scottrade - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

25-07-2014: MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia ... [Published Bionity.com - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

(GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) and Galapagos NV (Euronext: GLPG; OTC: GLPYY) announced today that the first program from their strategic alliance has advanced into preclinical development. MOR106 ... [Published Virtual Strategy Magazine - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Alzheimer's drug market 'set to triple by 2023'

Sales of drugs to treat Alzheimer’s disease are set to more than triple by 2023, reaching nearly $12 billion in seven major markets by that date, say new forecasts. This fast growth will be largely the result of expected launches of the first disease-modifying ... [Published Pharma Times - Jul 22 2014]

Quotes

...Arndt Schottelius, Chief Development Officer of MorphoSys AG. "With regards to MOR208, we intend to present first results from the ongoing NHL trial before year-end."
"The second quarter saw excellent progress with regard to partnering our latest Ylanthia antibody technology. With Merck Serono and the Temple University's Moulder Center for Drug Discovery two new alliances were initiated that have the potential to expand our pipeline of exciting new drug candidates" stated Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
"The impact of our next-generation antibody technology Ylanthia is increasingly visible in our portfolio. Ylanthia is ideally suited for therapeutic antibody discovery in a variety of fields including immuno-oncology, cancer stem cells and many more. The opportunity created by applying our antibody capabilities in the GPCR target space, for instance, could be enormous and we have just begun to scratch the surface by adding two new GPCR-programs to our portfolio" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG
The potential to apply the compound to multiple indications attracted investors. "We found Atox Bio's approach to modulating the immune response towards solving serious infections with significant unmet need to be unique and promising. AB103 may be applicable to treating patients suffering from a variety of indications for which no other therapies currently exist" OrbiMed Israel Managing Director Erez Chimovits said in a statement. - read the release and FierceBiotech 's take

More Content

All (81) | News (55) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (21)
sort by: Date | Relevance
MorphoSys Provides Update on the Company's Prop... [Published Technology Networks - 12 hours ago]
MorphoSys highlights pipeline as Q2 shows loss [Published MedNous - Jul 28 2014]
MorphoSys' (MPSYF) CEO Simon Moroney on Q2 2014... [Published Seeking Alpha - Jul 28 2014]
Alzheimer’s therapies could result in $12B mark... [Published MolecularImaging.net - Jul 28 2014]
Share buy-back week 30/2014 [Published EuroInvestor - Jul 28 2014]
Morphosys AG gives FY 2014 guidance in line wit... [Published Reuters UK - Jul 28 2014]
BRIEF-Morphosys shares rise after Q2 results [Published Reuters UK - Jul 28 2014]
MorphoSys Provides Update on the Company's Prop... [Published Virtual Strategy Magazine - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Virtual Strategy Magazine - Jul 28 2014]
MorphoSys H1 Profit Decreases; Re-confirms Guid... [Published RTTNews.com - Jul 28 2014]
BRIEF-Morphosys affirms outlook after Q2 loss [Published Reuters UK - Jul 28 2014]
MorphoSys Provides Update on the Company's Prop... [Published Value Investing News - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Value Investing News - Jul 28 2014]
MorphoSys Provides Update on the Company's Prop... [Published GlobeNewswire: Defense News - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published GlobeNewswire: Advertising News - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published Pettinga Financial Advisors - Jul 28 2014]
MorphoSys AG Reports Results for the First Six -2- [Published Scottrade - Jul 28 2014]
MorphoSys Provides Update on the Company's Prop... [Published OSIX News - Jul 28 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published Bionity.com - Jul 25 2014]
Big Pharma to share abandoned drugs, Actelion M... [Published FierceBiotech - Jul 25 2014]
Xencor to Host Second Quarter 2014 Financial Re... [Published Digital Journal - Jul 24 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published Virtual Strategy Magazine - Jul 23 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published Value Investing News - Jul 23 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
Alzheimer's drug market 'set to triple by 2023' [Published Pharma Times - Jul 22 2014]
Alzheimer's disease market forecast to reach ne... [Published Center Watch - Jul 22 2014]
Pre-Filled Syringes Market (2nd Edition), 2014 ... [Published RCL Advisors - Jul 21 2014]
MorphoSys to Host Q2 2014 Conference Call on 28... [Published Value Investing News - Jul 21 2014]
MorphoSys to Host Q2 2014 Conference Call on 28... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
MorphoSys gets additional patents on Ylanthia i... [Published PBR - News - Jul 21 2014]
MorphoSys has announced that the US Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the Company's latest antibody platform Ylanthia. ...
MorphoSys, Merck Serono to develop new therapeu... [Published PBR - News - Jun 13 2014]
MorphoSys and Merck have signed co-development and license agreement to discover and develop therapeutic antibodies against undisclosed immune checkpoints. ...
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: Cr... [Published Proactiveinvestors United Kingdom website - May 20 2014]
Asia The Nikkei 225 (+0.49%) rose for the first time in 5 days after pulling off from its recent 1-month low, following on from the positive lead seen on Wall Street. Elsewhere, Chinese stocks trade higher with both the Shanghai Comp (+0.1%) and Hang ...
[tt] [GRG] Increased Muscle Mass for the Elderly [Published TranshumanTech - Apr 30 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Hello, muscle wasting (sarcopenia) is a disease.  Depriving the general population of a cure for a universal disease on the grounds that the drug could be abused by athletes ...
Discount Packages on Global Trends and Developm... [Published PR.com Press Releases - Apr 04 2014]
New York, NY, April 04, 2014 --( PR.com )-- The global biotechnology and pharmaceutical market have seen significant positive sentiments in the recent years, especially with innovation contributing to the availability of a range of new treatments for ...
1

Press Releases

sort by: Date | Relevance
MorphoSys Provides Update on the Company's Prop... [Published GlobeNewswire: Defense News - Jul 28 2014]
MorphoSys AG Reports Results for the First Six ... [Published GlobeNewswire: Advertising News - Jul 28 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
MorphoSys and Galapagos Advance Joint Antibody ... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
MorphoSys to Host Q2 2014 Conference Call on 28... [Published GlobeNewswire: Acquisitions News - Jul 21 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.